期刊文献+

蔗糖铁注射液治疗肾性贫血30例疗效观察 被引量:3

Observation on the effect of sucrofer injection on 30 renal anemia patients
下载PDF
导出
摘要 目的观察蔗糖铁注射液治疗腹膜透析患者铁缺乏的有效性和安全性。方法选择60例长期不卧床腹膜透析(CAPD)的患者(透析龄>3个月),肾性贫血程度血红蛋白(HB<90g/L)或红细胞压积(HCT)<30%,随机分为静脉组与口服组,分别采用静脉注射蔗糖铁及口服富马酸亚铁进行补铁治疗,总疗程8周,检测治疗前治疗后8周时血清铁指标,红细胞相关指标及肝肾功能、电解质变化,并对不良反应进行监测。结果静脉注射蔗糖铁可以显著提高铁缺乏CAPD患者的Hb、HCt、TSAT、SF,效果优于口服富马酸亚铁组,并且无明显副作用。结论静脉注射蔗糖铁治疗CAPD患者铁缺乏,改善肾性贫血安全有效。
作者 云曼丽
出处 《中国热带医学》 CAS 2008年第12期2167-2168,2184,共3页 China Tropical Medicine
  • 相关文献

参考文献13

  • 1Muirhead N,Bergman J,Burgess E,et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin [J].Am J kidney Dis,1995,26:(suppl 1)s1-4.
  • 2张凌.慢性肾功能不全患者促红细胞生成素与铁剂的合理应用[J].中国全科医学,2004,7(16):1111-1112. 被引量:7
  • 3Danielson BG.structure,chemistry,and pharmacokinetics of intravenous iron agents[J]. J Am Soc Nephrol, 2004,15.supp12:s93-s98.
  • 4Fishbane S,Kowalski EA.The comparative safety of intravenous iron dextran,iron saccharate,and sodium ferric gluconate[J].Semin dial,2000,13:381-384.
  • 5Charytan C,Levin N,A1-Saloum M,et al.Efficacy and safety of iron sucrose for iron deficiency in patiends with dialysis-associated anemia:North American Clinical Trial [J].Am J Kidney Dis, 2001,37:300-307.
  • 6Michael B,Coyne DW,Fishbane S,at al.Sodium ferric gluconate complex in hemodialysis patients:adverse reactions compared to placebo and iron dextran [J].Kidney Int, 2002,61:1830-1839.
  • 7袁群生,郑法雷,丁峰,姜筠,郭王,黄峰先,王质刚,余学清,谌贻璞,顾勇,单渊东.蔗糖铁注射液治疗血液透析患者肾性贫血的多中心研究[J].中华肾脏病杂志,2004,20(1):51-55. 被引量:117
  • 8Silverstein SB,Rodgers GM.Parenteral iron therapy options.[J].Am J Hematol,2004,76:74-78.
  • 9Hamstra RD,Block MH,Schocket AL.Lntravenous iron dextran in clinical medicine[ J ].JAMA,1980,243:1726-1731.
  • 10Fishbane S,Ungureanu VD,Maesaka JK,et al.The safety of intravenous iron dextran in hemodialysis [J].Am J Kidney Dis, 1996,28:529-534

二级参考文献10

  • 1EschbachJW,EgrieJC,DowningMR.Correctionoftheanemiaofend-stagerenaldiseasewithrecombinanthumanerythropoietin[].The New England Journal of Medicine.1987
  • 2MacdougallIC.Monitoringofironstatusandironsupplementationinpatientstreatedwitherythropoietin[].CurrOpinionNephrolHy-pertens.1994
  • 3LevinNW,LazarusJM,NissensonAR.NationalCooperativerHuErythropoietinStudyinpatientswithchronicrenalfailure:aninterimreport[].AmJKidneyDis.1993
  • 4.NKF-DOQIclinicalpracticeguidelinesforthetreatmentofanemiaofchronicrenalfailure[].AmJKidneyDis.1997
  • 5CharytanC,LevinN,SaloumMA.Efficacyandsafetyofironsucroseforirondeficiencyinpatientswithdialysis-associatedanemia:NorthAmericanClinicalTrial[].AmJKidneyDis.2001
  • 6MichaelB,CoyneDW,StevenC.Sodiumferricgluconatecom-plexinhemodialysispatients:adversereactionscomparedtoplaceboandirondextran[].Kidney International.2002
  • 7FishbaneS,FreiGL,MaesakaJ.Reductioninrecombinanthu-manerythropoietinJosesbytheuseofchromicintravenousironsupplementation[].AmJKidneyDis.1995
  • 8KanakakornK,CavillI,JacobsA.Themetabolismofintra-venouslyadministerediron-dextran[].BrJHaem.1973
  • 9CavillI,MacdougallIC.Erythropoiesisandironsupplyinpatientstreatedwitherythropoietin[].Erythropoiesis new dimensions in the treatment of anaemia.1992
  • 10HamstraRD,BlockMH,SchockerA.Intravenousirondextraninclinicalmedicine[].The Journal of The American Medical Association.1980

共引文献122

同被引文献38

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部